ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

FATE Fate Therapeutics Inc

4.04
0.00 (0.00%)
Pre Market
Last Updated: 10:40:59
Delayed by 15 minutes
Share Name Share Symbol Market Type
Fate Therapeutics Inc NASDAQ:FATE NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.04 3.95 4.36 242 10:40:59

Fate Therapeutics to Present at Upcoming Investor Conferences

01/09/2017 1:00pm

GlobeNewswire Inc.


Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Fate Therapeutics Charts.

Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Scott Wolchko, President and Chief Executive Officer, will be presenting at three upcoming investor conferences in September:

  • 2017 Wells Fargo Healthcare Conference at 8:15 a.m. ET on Thursday, September 7, 2017 in Boston, MA.
  • Cantor Fitzgerald Global Healthcare Conference at 10:20 a.m. ET on Tuesday, September 26, 2017 in New York, NY.
  • Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology at 10:00 a.m. ET on Thursday, September 28, 2017 in New York, NY.

Live webcasts of the presentations will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcasts, archived replays of each presentation will be available on the Company's website for 30 days after the respective conference. 

About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company's hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cell lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Its adoptive cell therapy programs are based on the Company's novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com

1 Year Fate Therapeutics Chart

1 Year Fate Therapeutics Chart

1 Month Fate Therapeutics Chart

1 Month Fate Therapeutics Chart

Your Recent History

Delayed Upgrade Clock